The medical device maker expects full-year earnings to land near the bottom end of its forecast range, and has written down its investment in Saluda.
Cochlear shares hit three-year low on new implant delays
The medical device maker expects full-year earnings to land near the bottom end of its forecast range, and has written down its investment in Saluda.
